JOINING JACK — grant history
Latest income
£890k
Grants listed (FY2025)
45
Listed grants total
£5.8m
Accounts grants total
£505k
listed grants do not fully reconcile with the accounts total — list may be partialextracted from its FY2025 accounts
What this funder supports
Where grantees operate
- Northern Ireland
- Scotland
- Throughout England And Wales
What changed: FY2023 → FY2025
| Change | Grantee | FY2023 | FY2025 |
|---|---|---|---|
| new | Queen Square Institute of Neurology, London | — | £441k |
| new | Reveragen BioPharma Inc, USA | — | £400k |
| new | Dr Dirk Fischer, University Children’s Hospital Basel | — | £230k |
| new | Dr Olivier Dorchies, University of Geneva | — | £200k |
| new | Leeds Teaching Hospital | — | £200k |
| new | Aparito | — | £173k |
| new | Spinal Muscular Atrophy UK (SMA UK) & University of Liverpool | — | £150k |
| new | Dr De Geode, Royal Preston Hospital | — | £118k |
| up | Solid GT, Boston, USA | £400k | £1.7m |
| not listed | Beveseesn BioPharma Inc, USA | £400k | — |
| not listed | University Children’s Hospital Basel | £230k | — |
| not listed | University of Geneva | £200k | — |
| not listed | Royal Preston Hospital | £118k | — |
| not listed | Freeman Hospital | £67k | — |
| not listed | MUSCULAR DYSTROPHY GROUP OF GREAT BRITAIN AND NORTHERN IRELAND | £55k | — |
| not listed | The University of Western Australia | £50k | — |
| not listed | University of Liverpool | £36k | — |
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Solid GT, Boston, USA | FY2025 | £1.7m | Gene therapy |
| Queen Square Institute of Neurology, London | FY2025 | £441k | Virtual Hospitals |
| Reveragen BioPharma Inc, USA | FY2025 | £400k | VBP-15, Phase 1 Clinical Trial |
| Dr Dirk Fischer, University Children’s Hospital Basel | FY2025 | £230k | Open label extension study for Tamoxifen |
| Dr Olivier Dorchies, University of Geneva | FY2025 | £200k | Preclinical study of the combination of tamoxifen, Lcitrulline and metformin |
| Leeds Teaching Hospital | FY2025 | £200k | DMD Care Transition |
| EVOX Therapeutics | FY2025 | £200k | New ways of delivering Gene Therapy |
| Dr Dirk Fischer, University Children’s Hospital Basel | FY2025 | £195k | Tamoxifen Clinical Trial |
| University of Florida | FY2025 | £185k | Immunology Grant |
| Aparito | FY2025 | £173k | Home-based video assessment of DMD |
| Spinal Muscular Atrophy UK (SMA UK) & University of Liverpool | FY2025 | £150k | Smart Suit Project |
| Newcastle University | FY2025 | £150k | DMD Care Phase 2 |
| University of Minnesota | FY2025 | £140k | Stem Cells |
| Newcastle University | FY2025 | £140k | DMD Care UK |
| Alder Hey Children’s Hospital, Liverpool | FY2025 | £127k | ST4 Neuromuscular Clinical Research Doctor |
| Dr De Geode, Royal Preston Hospital | FY2025 | £118k | Hydrotherapy Clinical Trial |
| Akashi Therapeutics, USA | FY2025 | £100k | Phase1/2 Clinical trial of HT-100 |
| Summit Corporation, Oxford, UK | FY2025 | £100k | Developing biomarkers for Utrophin Modulators |
| Dr Dirk Fischer, University Children’s Hospital Basel | FY2025 | £97k | Tamoxifen Project Manager |
| University of Newcastle | FY2025 | £79k | TREAT-NMD DMD Co-Ordinator Role |
| University of Glasgow | FY2025 | £75k | DMD Care Neuropsychiatrist |
| Dr John Bourke, Freeman Hospital | FY2025 | £67k | Understanding heart disease in DMD |
| The Duchenne Forum, Muscular Dystrophy Campaign | FY2025 | £55k | Supporting 8 basic research projects |
| Dr Peter Arthur, Senior Lecturer, The University of Western Australia | FY2025 | £50k | Taurine |
| Whizz Kidz | FY2025 | £50k | Dream Chair development |
| Alder Hey Children’s Hospital, Liverpool | FY2025 | £46k | Physiotherapist |
| Dr Addolorata Pisconti, University of Liverpool | FY2025 | £36k | Use of Elastase Inhibitors to Treat DMD |
| Dr Guglieri, University of Newcastle | FY2025 | £36k | Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy |
| Dr Anne-Marie Childs, Leeds Children’s Hospital | FY2025 | £35k | DMD Hub research Fellow/ Clinical Trial Support |
| Newcastle University | FY2025 | £33k | Antifibrotic/antiadipogenic drug Fibrogenesis |
| Alder Hey Children’s Hospital, Liverpool | FY2025 | £32k | Duchenne Clinical Research Nurse |
| Alder Hey Children’s Hospital, Liverpool | FY2025 | £31k | F2 Neuromuscular Clinical Research Doctor |
| Prof Steve Winder, University of Sheffield | FY2025 | £31k | Investigating soy products as a treatment for DMD |
| Agada Biosciences | FY2025 | £25k | Tackling fibrosis and muscle regeneration |
| Dr Olivier Dorchies, University of Geneva | FY2025 | £25k | Repurposing Drugs |
| Royal Victoria Infirmary, Newcastle | FY2025 | £23k | Duchenne Clinical Trial Nurse |
| Duke University | FY2025 | £20k | Biomarker Trial |
| Dr Spinty, Alder Hey | FY2025 | £14k | DMD Heart Protection Study |
| Prf Volker Straub, University of Newcastle | FY2025 | £10k | Testosterone extension |
| Dr Chiara Marini-Bettolo, University of Newcastle | FY2025 | £10k | Adult NMCCC |
| Dr Lee Borthwich, University of Newcastle | FY2025 | £10k | Fibrosis |
| Newcastle University | FY2025 | £10k | Splint Trial |
| Leiden University | FY2025 | £10k | Vitamin B3 |
| Dr Keith Foster, The University of Reading | FY2025 | £6k | Assessing the preclinical therapeutic impact of cannabidiol for DMD |
| Professor Kanneboyina Nagaraju at Binghamton, the State University of New York | FY2025 | £1k | Immunology Grant Call Award |
| Beveseesn BioPharma Inc, USA | FY2023 | £400k | vee-15, Phase 1 Ginical Trial |
| Solid GT, Boston, USA | FY2023 | £400k | sene therapy |
| University Children’s Hospital Basel | FY2023 | £230k | Tr = study for Or |
| University of Geneva | FY2023 | £200k | Preclinical study of the combination of tamoxifen, L-citrulline and metformin |
| EVOX Therapeutics | FY2023 | £200k | New ways of delivering Gene |
| University Children’s Hospital Basel | FY2023 | £195k | Tamoxifen Clinical Trial |
| University of Florida | FY2023 | £185k | Immunology Grant |
| University of Minnesota | FY2023 | £140k | Stem cells |
| Newcastle University | FY2023 | £140k | DMD Care UK |
| Alder Hey Children’s Hospital, Liverpool | FY2023 | £127k | ST4 Neuromuscular Clinical |
| Royal Preston Hospital | FY2023 | £118k | Hydrotherapy Clinical Trial |
| Akashi Therapeutics, USA | FY2023 | £100k | Phase1/2 Clinical trial of HT-100 |
| University Children’s Hospital Basel | FY2023 | £97k | Tamoxifen Project Manager |
| University of Newcastle | FY2023 | £79k | |
| University of Glasgow | FY2023 | £75k | DMD Care Neuropsychiatrist |
| Freeman Hospital | FY2023 | £67k | Or John Bourke |
| Muscular Dystrophy Campaign | FY2023 | £55k | The Duchenne Forum, Supporting 8 |
| Whizz Kidz | FY2023 | £50k | Dream Chair development |
| The University of Western Australia | FY2023 | £50k | Taurine |
| Alder Hey Children’s Hospital, Liverpool | FY2023 | £46k | Physiotherapist |
| University of Liverpool | FY2023 | £36k | Elastase Inhibitors to Treat |
| University of Newcastle | FY2023 | £36k | Co-Funded Lectureship for a |
| Newcastle University | FY2023 | £33k | Antifibrotic/antiadipogenic drug |
| Alder Hey Children’s Hospital, Liverpool | FY2023 | £32k | Duchenne Clinical Research Nurse |
| Alder Hey Children’s Hospital, Liverpool | FY2023 | £31k | Neuromuscular Clinical Research |
| University of Sheffield | FY2023 | £31k | investigating soy products as a |
| Agada Biosciences | FY2023 | £25k | Tackling fibrosis and muscle |
| University of Geneva | FY2023 | £25k | Repurposing Drugs |
| Royal Victoria Infirmary, Newcastle | FY2023 | £23k | Duchenne Clinical Trial Nurse |
| Duke University | FY2023 | £20k | Biomarker Trial |
| Alder Hey | FY2023 | £14k | ow Heart Protection Study |
| University of Newcastle | FY2023 | £10k | Ferosis Or |
| University of Newcastle | FY2023 | £10k | Acute tranacec |
| University of Newcastle | FY2023 | £10k | Testosterone extension |
| Leiden University | FY2023 | £10k | Vitamin B3 |
| Newcastle University | FY2023 | £10k | Sout Trial |
| The University of Reading | FY2023 | £6k | Assessing the preclinical therapeutic impact of cannabidiol for DAD |
| Binghamton, the State University of New York | FY2023 | £1k | Immunology Grant Call Award |
| Solid GT, Boston, USA | FY2022 | £1.3m | Gene therapy |
| Reveragen BioPharma Inc, USA | FY2022 | £312k | VBP-15, Phase 1 Clinical Trial |
| University Children’s Hospital Basel | FY2022 | £230k | Open label extension study for Tamoxifen |
| EVOX Therapeutics | FY2022 | £200k | New ways of delivering Gene Therapy |
| University of Geneva | FY2022 | £200k | Preclinical study of the combination of tamoxifen, Lcitrulline and metformin |
| University Children’s Hospital Basel | FY2022 | £195k | Tamoxifen Clinical Trial |
| University of Florida | FY2022 | £185k | Immunology Grant |
| University of Minnesota | FY2022 | £140k | Stem Cells |
| Newcastle University | FY2022 | £140k | DMD Care UK |
| Alder Hey Children’s Hospital, Liverpool | FY2022 | £127k | ST4 Neuromuscular Clinical Research Doctor |
| Royal Preston Hospital | FY2022 | £118k | Hydrotherapy Clinical Trial |
| Summit Corporation, Oxford, UK | FY2022 | £100k | Developing biomarkers for Utrophin Modulators |
| University Children’s Hospital Basel | FY2022 | £97k | Tamoxifen Project Manager |
| University of Newcastle | FY2022 | £79k | TREAT-NMD DMD Co-Ordinator Role |
| Akashi Therapeutics, USA | FY2022 | £78k | Phase1/2 Clinical trial of HT-100 |
| University of Glasgow | FY2022 | £75k | DMD Care Neuropsychiatrist |
| Freeman Hospital | FY2022 | £67k | Understanding heart disease in DMD |
| Muscular Dystrophy Campaign | FY2022 | £55k | The Duchenne Forum, Supporting 8 basic research projects |
| Whizz Kidz | FY2022 | £50k | Dream Chair development |
| The University of Western Australia | FY2022 | £50k | Taurine |
| Alder Hey Children’s Hospital, Liverpool | FY2022 | £46k | Physiotherapist |
| University of Liverpool | FY2022 | £36k | Use of Elastase Inhibitors to Treat DMD |
| University of Newcastle | FY2022 | £36k | Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy |
| Newcastle University | FY2022 | £33k | Antifibrotic/antiadipogenic drug Fibrogenesis |
| Alder Hey Children’s Hospital, Liverpool | FY2022 | £32k | Duchenne Clinical Research Nurse |
| Alder Hey Children’s Hospital, Liverpool | FY2022 | £31k | F2 Neuromuscular Clinical Research Doctor |
| University of Sheffield | FY2022 | £31k | Investigating soy products as a treatment for DMD |
| University of Geneva | FY2022 | £25k | Repurposing Drugs |
| Agada Biosciences | FY2022 | £25k | Tackling fibrosis and muscle regeneration |
| Royal Victoria Infirmary, Newcastle | FY2022 | £23k | Duchenne Clinical Trial Nurse |
| Duke University | FY2022 | £20k | Biomarker Trial |
| Alder Hey | FY2022 | £14k | DMD Heart Protection Study |
| Leiden University | FY2022 | £10k | Vitamin B3 |
| University of Newcastle | FY2022 | £10k | Testosterone extension |
| University of Newcastle | FY2022 | £10k | Adult NMCCC |
| University of Newcastle | FY2022 | £10k | Fibrosis |
| Newcastle University | FY2022 | £10k | Splint Trial |
| The University of Reading | FY2022 | £6k | Assessing the preclinical therapeutic impact of cannabidiol for DMD |
| Binghamton, the State University of New York | FY2022 | £1k | Immunology Grant Call Award |